A clinical trial of intraoperative near-infrared imaging to assess tumor extent and identify residual disease during anterior mediastinal tumor resection.
Citations
89 citations
26 citations
21 citations
11 citations
7 citations
References
1,000 citations
"A clinical trial of intraoperative ..." refers methods in this paper
...ICG has commonly been used in the clinic as a tool for evaluating perfusion by NIR angiography.(20,21) As a perfusion agent, ICG is delivered at a dose of 0....
[...]
...4 mg/kg, with fluorescence imaging occurring in the first window after the intravenous infusion (within 10-20 minutes).(15,20,21)...
[...]
367 citations
"A clinical trial of intraoperative ..." refers methods in this paper
...ICG has commonly been used in the clinic as a tool for evaluating perfusion by NIR angiography.(20,21) As a perfusion agent, ICG is delivered at a dose of 0....
[...]
...4 mg/kg, with fluorescence imaging occurring in the first window after the intravenous infusion (within 10-20 minutes).(15,20,21)...
[...]
139 citations
"A clinical trial of intraoperative ..." refers background or methods or result in this paper
...This approach has been successful in the context of central nervous system tumors,(15) pulmonary metastases,(9) and primary lung neoplasms.(12) In this trial, we found ICG-based NIR imaging safe, with no patients experiencing drug-related toxicity....
[...]
...Our group initially explored this approach in clinical trials involving patients with pulmonary metastases(9) and non–small cell lung cancer.(12) In these feasibility studies, NIR imaging was capable of identifying both subcentimeter malignant lesions and positive margins....
[...]
...Mechanistically, intratumoral accumulation appears to be driven by the presence of abnormal endothelial cells and the high vascularity of these lesions; this suggests a role for EPR, as has been described by our group.(9,12,18)...
[...]
...The low toxicity further authenticates the safety profile that we observed in experiences with second-window ICG for neurologic malignancies and thoracic malignancies.(9,12,15)...
[...]
...Notably, dosing parameters were determined on the basis of preclinical data involving thymoma models(14) and previous human data involving other pleural-based and intrapulmonary neoplasms.(9,12,18)...
[...]
109 citations
"A clinical trial of intraoperative ..." refers methods or result in this paper
...4 mg/kg, with fluorescence imaging occurring in the first window after the intravenous infusion (within 10-20 minutes).(15,20,21)...
[...]
...The low toxicity further authenticates the safety profile that we observed in experiences with second-window ICG for neurologic malignancies and thoracic malignancies.(9,12,15)...
[...]
...In situ, real-time fluorescence imaging was performed using 2 systems optimized for the detection of ICG, Artemis Handheld Fluorescence Imaging System (Quest Medical Imaging, Middenmeer, the Netherlands) and Visionsense VS3 Iridium (VisionSense Corp, Philadelphia, Pennsylvania), as previously described.(9,15,16) The Artemis imaging system was used for subjects 1 to 10, whereas Iridium was used for subjects 11 to 25....
[...]
...Twenty-four hours before resection, all subjects received intravenous ICG (5 mg/kg) at the University of Pennsylvania Health System’s Clinical Translational Research Center.9,15 Patients were monitored for 30 minutes and then discharged....
[...]
...Twenty-four hours before resection, all subjects received intravenous ICG (5 mg/kg) at the University of Pennsylvania Health System’s Clinical Translational Research Center.(9,15) Patients were monitored for 30 minutes and then discharged....
[...]
96 citations
"A clinical trial of intraoperative ..." refers background in this paper
...When these delivery parameters are implemented, ICG functions by exploiting abnormally leaky capillaries and increased pressure gradients (also known as the EPR effect), which are found in most solid malignancies.(13)...
[...]
...EPR permits nanostructures (between 10 nm and 100 nm) to accumulate in solid malignancies as a result of leaky vasculature and the lack of lymphatics.(13) Our group initially explored this approach in clinical trials involving patients with pulmonary metastases(9) and non–small cell lung cancer....
[...]